Massmutual Trust Co. FSB ADV Has $54,000 Stake in Hologic, Inc. (NASDAQ:HOLX)

Massmutual Trust Co. FSB ADV increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 24.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 691 shares of the medical equipment provider’s stock after purchasing an additional 137 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Hologic were worth $54,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in HOLX. Norges Bank bought a new position in shares of Hologic in the fourth quarter valued at about $217,529,000. The Manufacturers Life Insurance Company raised its position in shares of Hologic by 117.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock valued at $154,598,000 after purchasing an additional 1,168,564 shares during the period. Qube Research & Technologies Ltd raised its position in shares of Hologic by 117.2% in the third quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider’s stock valued at $95,651,000 after purchasing an additional 743,557 shares during the period. Jennison Associates LLC bought a new position in Hologic during the fourth quarter worth about $30,079,000. Finally, Clearbridge Investments LLC bought a new position in Hologic during the third quarter worth about $25,398,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on HOLX shares. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Evercore ISI raised their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and raised their price target for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Argus lifted their target price on shares of Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and an average target price of $85.60.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $73.07 on Friday. The company’s 50-day moving average is $74.59 and its 200 day moving average is $74.17. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.29 and a current ratio of 3.97. The company has a market capitalization of $17.05 billion, a P/E ratio of 37.28, a price-to-earnings-growth ratio of 2.40 and a beta of 1.00. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $82.45.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The firm’s quarterly revenue was down .8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.06 EPS. On average, equities research analysts forecast that Hologic, Inc. will post 4.08 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.